Search Results - "Dhaver, Shilton"

1800-PUB: The Long-Term Effect of Glucagon-Like Peptide 1 Receptor Agonists on Glycemic Control Is Predominantly Related to Weight Loss by AL-BADRI, MARWA, DHAVER, SHILTON E., SALAH, TAREQ, KIBAA, KARIM, KHATER, ABDELRAHMAN, MCCARRAGHER, RYAN, DEMATTOS, LILY, AL-ROOMI, FATIMAH, HAMDY, OSAMA

“…Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) are established treatment options for type 2 diabetes (T2D). In addition to their glycemic benefit, they…”
Get full text

1565-P: Relationship between Glycemic Control, Body Weight, and Nonalcoholic Fatty Liver Disease in Patients with Type 1 Diabetes by DHAVER, SHILTON E., SALAH, TAREQ, AL-BADRI, MARWA, KIBAA, KARIM, KHATER, ABDELRAHMAN, MCCARRAGHER, RYAN, AL-ROOMI, FATIMAH, DEMATTOS, LILY, HAMDY, OSAMA

“…Increased body weight is a common risk factor for nonalcoholic fatty liver disease (NAFLD). Although the prevalence of overweight and obesity among patients…”
Get full text

416-P: Effect of Intensive Lifestyle Intervention on Renal Function in Patients with Diabetes and Obesity—A 10-Year Longitudinal Study by SALAH, TAREQ, AL-BADRI, MARWA, DHAVER, SHILTON E., KHATER, ABDELRAHMAN, KIBAA, KARIM, MCCARRAGHER, RYAN, HAMDY, OSAMA

“…Diabetic nephropathy is a common complication of diabetes mellitus (DM). In this study, we evaluated renal function in patients with DM and obesity 10 years…”
Get full text

441-P: Long-Term Effects of Intensive Lifestyle Intervention in Real-World Clinical Practice on Cardiometabolic Outcomes in Patients with Diabetes—A 15-Year Longitudinal Study by KHATER, ABDELRAHMAN, AL-BADRI, MARWA, SALAH, TAREQ, DHAVER, SHILTON E., KIBAA, KARIM, MCCARRAGHER, RYAN, HAMDY, OSAMA

“…We previously demonstrated that achieving and maintaining ≥7% weight loss at one year in patients with diabetes (DM), through multidisciplinary intensive…”
Get full text

31-OR: Almond Milk Has No Additional Benefits over 2% Milk on Postprandial Glycemia, Lipidemia, and Gastrointestinal Hormones in Patients with Type 2 Diabetes by MITRI, JOANNA, TOMAH, SHAHEEN, DREYFUSS, JONATHAN, AL-BADRI, MARWA, DHAVER, SHILTON E., GARDNER, HANNAH, TASABEHJI, MHD WAEL, HAMDY, OSAMA

“…Almond milk is often used in lieu of dairy milk with the perception of being a healthier substitute, however, its effect on postprandial glycemia compared to…”
Get full text

1261-P: Prevalence of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 1 Diabetes by SALAH, TAREQ, TOMAH, SHAHEEN, AL-BADRI, MARWA, KIBAA, KARIM, DHAVER, SHILTON E., CURRY, MICHAEL P., LAI, MICHELLE, JIANG, ZHENGHUI, KHATER, ABDELRAHMAN, MCCARRAGHER, RYAN, DEMATTOS, LILY, TRAN, MINH, HAMDY, OSAMA

“…Nonalcoholic fatty liver disease (NAFLD) is a common comorbid condition in patients with type 2 diabetes. However, little is known about its prevalence among…”
Get full text

733-P: Diabetes Remission Outcomes Protocol (DROP)—Early Observation by KIBAA, KARIM, DHAVER, SHILTON E., JOHNSON, COLLEEN, VOTTA, JENNIE L., SHAHAR, JACQUELINE I., MITCHELL, CHRISTINE, BEATON, JOAN M., SALAH, TAREQ, AL-BADRI, MARWA, KHATER, ABDELRAHMAN, MCCARRAGHER, RYAN, HAMDY, OSAMA

“…A 12-week multidisciplinary intensive lifestyle intervention (ILI) was shown to induce diabetes remission (A1C <6.5%, on no medications for ≥3 months),…”
Get full text

976-P: Evaluation of Hybrid Closed-Loop Insulin Delivery System for Patients with Type 1 Diabetes in Real-World Clinical Practice: A One-Year Qualitative Observational Study by ELDIB, AHMED H., TOMAH, SHAHEEN, DHAVER, SHILTON E., GARDNER, HANNAH, TASABEHJI, MHD WAEL, ALBADRI, MARWA, ATAKOV-CASTILLO, ASTRID, TOSCHI, ELENA, HAMDY, OSAMA

“…The MiniMed™ 670G (670G) is the first FDA approved hybrid closed-loop insulin delivery system for patients with type 1 diabetes (T1D). In Auto Mode, the…”
Get full text

1105-P: Moderate-to-Advanced Liver Fibrosis Is Common in Patients with Type 1 Diabetes (T1D) and Nonalcoholic Fatty Liver Disease (NAFLD) by TOMAH, SHAHEEN, SALAH, TAREQ, AL-BADRI, MARWA, DHAVER, SHILTON E., CURRY, MICHAEL P., JIANG, ZHENGHUI, LAI, MICHELLE, ELENANI, OMNIA A., KIBAA, KARIM, GARDNER, HANNAH, MCCARRAGHER, RYAN, KAUSHIK, AARYA A., ZIEMNIAK, NOLAN A., HAMDY, OSAMA

“…ADA guidelines recommend screening for significant fibrosis in patients with type 2 diabetes and steatosis or elevated ALT. In contrast, there are limited or…”
Get full text

In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity by Al-Badri, Marwa, Kilroy, Cara L., Shahar, Jacqueline Ifat, Tomah, Shaheen, Gardner, Hannah, Sin, Mallory, Votta, Jennie, Phillips-Stoll, Aliza, Price, Aaron, Beaton, Joan, Davis, Chandra, Rizzotto, Jo-Anne, Dhaver, Shilton, Hamdy, Osama

“…Background: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a…”
Get full text

真实世界糖尿病实践中强化生活方式干预对与基线HbA1C相关的HbA1C改善幅度以及体重减轻的影响:13年观察 by Eldib, Ahmed H, Dhaver, Shilton, Al‐Badri, Marwa, Salah, Tareq, Kibaa, Karim, Elenani, Omnia, Tomah, Shaheen, Gardner, Hannah, Hamdy, Osama

“…摘要 【摘要】 背景 强化生活方式干预(ILI)对于糖尿病患者的HbA1C效果被低估。HbA1C 的改善被认为依赖于体重的减少程度。在真实世界的临床实践中，本研究评估了在经历13年以上强化生活方式干预的糖尿病患者中，与基线HbA1C 相关的HbA1C 变化幅度与体重减轻程度。方法…”
Get full text

Hybrid model of intensive lifestyle intervention is potentially effective in patients with diabetes & obesity for post-COVID era by Dhaver, Shilton, Al-Badri, Marwa, Salah, Tareq, Kilroy, Cara, Shahar, Jacqueline, Johnson, Colleen, Votta, Jennie, Mitchell, Christine, Beaton, Joan, Khater, Abdelrahman, Kibaa, Karim, McCarragher, Ryan, Davis, Chandra, Hamdy, Osama

“…The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary intensive lifestyle intervention (ILI) for patients with…”
Get full text

Long-term effect of intensive lifestyle intervention on cardiometabolic risk factors and microvascular complications in patients with diabetes in real-world clinical practice: a 10-year longitudinal study by Tomah, Shaheen, Zhang, Hongxia, Al-Badri, Marwa, Salah, Tareq, Dhaver, Shilton, Khater, Abdelrahman, Tasabehji, Mhd Wael, Hamdy, Osama

“…IntroductionIntensive lifestyle intervention (ILI) has significantly reduced incidence of diabetes and improved many cardiovascular disease risk factors. We…”
Get full text

Multidisciplinary intensive lifestyle intervention improves markers of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes and obesity: a retrospective matched-cohort study by Tomah, Shaheen, Salah, Tareq, Al-Badri, Marwa, Dhaver, Shilton, Gardner, Hannah, Tasabehji, Mhd Wael, Hamdy, Osama

“…The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing among patients with type 1 diabetes (T1D) paralleling the increasing prevalence of…”
Get full text

408-P: Long-Term Improvement in Renal Function following Intensive Lifestyle Intervention in Patients with Diabetes and Obesity-A 15-Year Longitudinal Study by Salah, Tareq, Al-Badri, Marwa, Askar, Abd Almasih Barbar, Khater, Abdelrahman, Dhaver, Shilton E, Mottalib, Adham, Hamdy, Osama

“…Nearly 30% of patients with diabetes mellitus (DM) develop diabetic nephropathy over time. The long-term effect of weight loss, through lifestyle intervention,…”
Get full text

14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists by Al-Badri, Marwa, Askar, Abd Almasih Barbar, Khater, Abdelrahman, Salah, Tareq, Dhaver, Shilton E, Al-Roomi, Fatimah, Mottalib, Adham, Hamdy, Osama

“…Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) emerged as an important treatment option for type 2 diabetes (T2D) for their dual efficacy in improving…”
Get full text

Magnitude of A1C improvement in relation to baseline A1C and amount of weight loss in response to intensive lifestyle intervention in real‐world diabetes practice: 13years of observation by Eldib, Ahmed H, Shilton Dhaver, Marwa Al‐Badri, Salah, Tareq, Kibaa, Karim, Elenani, Omnia, Shaheen Tomah, Gardner, Hannah, Hamdy, Osama

“…BackgroundEffect of intensive lifestyle intervention (ILI) on A1C in participants with diabetes is underestimated. A1C improvement is presumed to be dependent…”
Get full text

Magnitude of A1C improvement in relation to baseline A1C and amount of weight loss in response to intensive lifestyle intervention in real-world diabetes practice: 13 years of observation by Eldib, Ahmed H, Dhaver, Shilton, Al-Badri, Marwa, Salah, Tareq, Kibaa, Karim, Elenani, Omnia, Tomah, Shaheen, Gardner, Hannah, Hamdy, Osama

“…Effect of intensive lifestyle intervention (ILI) on A1C in participants with diabetes is underestimated. A1C improvement is presumed to be dependent on the…”
Get full text

Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study by Eldib, Ahmed, Dhaver, Shilton, Kibaa, Karim, Atakov-Castillo, Astrid, Salah, Tareq, Al-Badri, Marwa, Khater, Abdelrahman, McCarragher, Ryan, Elenani, Omnia, Toschi, Elena, Hamdy, Osama

“…In 2016, the Food and Drug Administration approved the first hybrid closed-loop (HCL) insulin delivery system for adults with type 1 diabetes (T1D). There is…”
Get full text

121-LB: Early Independent View of Quality of Life in Patients with Type 1 Diabetes Using Hybrid Closed-Loop Insulin Delivery System in Real-World Clinical Practice by ELDIB, AHMED H., TOSCHI, ELENA, MAHMOUD, NOOR, TASABEHJI, MHD WAEL, ASHRAFZADEH, SAHAR, TOMAH, SHAHEEN, DHAVER, SHILTON EDWARD, ATAKOV-CASTILLO, ASTRID, ABDUL-GHANI, AHMED E., FARKOUH, KATIE, TREVINO, RAFAEL, HAMDY, OSAMA

“…The MiniMed™ 670G (670 HCL) is the first FDA-approved hybrid closed-loop insulin delivery system device for patients with type 1 diabetes (T1D). This study…”
Get full text